查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138273

全球癌症疫苗市場-2022-2029

Global Cancer Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

市場參與者對癌症疫苗的臨床試驗數量不斷增加，預計將推動市場增長。

胰腺導管腺癌，稱為 PDAC，是最常見的胰腺癌類型，尚無有效治療方法。 mRNA 疫苗製造商 BioNTech 發布了針對 PDAC 的疫苗的 1 期臨床試驗數據。 Bio-NTech 開發的一種 mRNA 疫苗用於將新抗原遺傳密碼傳遞到患者的細胞中。新抗原是癌細胞製造的蛋白質，由細胞製造的代碼指導。這種蛋白質的產生有助於觸發免疫系統對腫瘤本身的攻擊。此外，GSK plc 正在開發 BLENREP（belantamab mafodotin），這是一種針對成熟 B 細胞血清型的 ADC，用於治療多發性骨髓瘤。目前處於III期臨床試驗階段。

此外，根據牛津大學和路德維希癌症研究所的一項研究，牛津阿斯利康的 COVID-19 疫苗技術可能應用於癌症治療。當在動物腫瘤模型中進行評估時，這種癌症疫苗接種增強了癌症免疫療法的功效並增加了侵入腫瘤的抗腫瘤 T 細胞的水平。此外，免疫療法和疫苗聯合使用比單獨免疫療法顯示出更大的腫瘤縮小效果，提高了小鼠的存活率。此外，codagenix 獲得 FDA 批准其用於 CodaVax-RSV 的研究藥物申請，這是一種減毒鼻 RSV 疫苗候選者。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

癌症疫苗研發成本高、單一疫苗生產時間長、監管審批慢等預計會在預測期內阻礙市場。我來了。

行業分析

癌症疫苗市場根據各種行業因素（包括波特五力、未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行了深入分析。

COVID-19 影響分析

COVID-19 大流行對市場產生了適度的影響。隨著 COVID-19 病例數量的增加，世界各地的醫療保健系統都將重點放在疾病控制上，推遲了包括癌症在內的其他慢性病的預防、檢測和治療。牛津大學和阿斯利康公司的研究人員正在使用相同的方法來製造治療性癌症疫苗，並在動物研究中取得了可喜的結果。大流行之後，科學家和政□□府比以往任何時候都更加努力和更快地生產疫苗來控制病毒。因此，疫苗研究得到了發展。擺脫這場危機，信使 RNA 等技術將證明其治療癌症等其他疾病的有效性和潛力。這一進展發生在研究人員研究利用免疫系統對抗腫瘤的其他尖端癌症治療方法之際。

另一方面，大流行擾亂了癌症疫苗的供應鍊和流程。因此，COVID-19 大流行正在影響市場。但是，預計這種情況將在預測期內逐漸改善。

全球癌症疫苗市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
    • 市場進入者增加的癌症疫苗臨床試驗有望推動市場增長
  • 限制因素
    • 癌症疫苗開發的高成本預計將阻礙市場增長。
  • 機會
  • 影響分析

第5章行業分析

  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 預防癌症疫苗
  • 治療性癌症疫苗

第 8 章技術

  • 樹突狀細胞 (DC) 癌症疫苗
  • 重組癌症疫苗
  • 抗原/輔助癌症疫苗
  • 全細胞癌疫苗
  • 病毒載體和 DNA 癌症疫苗

第 9 章按癌症類型

  • 前列腺癌
  • 宮頸癌
  • 肺癌
  • 膀胱癌
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • ose-免疫
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck & Co. Inc.
  • IO Biotech
  • Medigene AG
  • Northwest Biotherapeutics
  • GlaxoSmithKline
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies Corporation
  • Immunophotonics
  • Codagenix（*LIST NOT EXHAUSTIVE）

第13章 DataM

簡介目錄
Product Code: DMPH1513

Market Overview

Cancer vaccines market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 18% during the forecast period (2022-2029).

Cancer is a malignant tumor caused by uncontrollable cell development in the body. It can be treated with a variety of drugs and vaccinations. Vaccines are widely classified as either preventative or therapeutic. Preventive cancer vaccinations are used to prevent oncovirus-caused cancer and to protect against human papillomavirus (HPV), whereas therapeutic vaccines stimulate the individual adaptive immune systems by employing tumor antigens. Cancer vaccines are available in various forms, including antigen, dendritic cell, and anti-idiotype.There are several vaccines such as personalized cancer vaccines, anthrax vaccines, and other types of vaccines.

Market Dynamics

Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.

Pancreatic Ductal Adenocarcinoma, also known as PDAC, is a prevalent type of pancreatic cancer for which there are no effective treatments. BioNTech, a manufacturer of mRNA vaccines, released phase-1 clinical trial data for its vaccine against PDAC. The neoantigen genetic code is delivered to the patient's cells using the mRNA vaccination created by BioNTech. The neoantigens, proteins made by cancer cells, are instructed to be produced by the cells by the code. The production of these proteins aids in triggering the immune system's attack on the tumor itself. Moreover, BLENREP (belantamab mafodotin), an ADC targeting B-cell maturation antigen type used to treat multiple myeloma, is being developed by GSK plc. It is now in Phase III.

Additionally, the Oxford-AstraZeneca COVID-19 vaccine's technology also has the potential to treat cancer, according to research from the University of Oxford and the Ludwig Institute for Cancer Research. The cancer vaccination improved the effectiveness of cancer immunotherapy when evaluated in animal tumor models, where it increased the levels of anti-tumour T cells invading the tumors. The combination of immunotherapy and the vaccine demonstrated a larger tumor size decrease than immunotherapy alone, and the mice's survival improved. Furthermore, codagenix received FDA clearance for an investigational new drug application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax-RSV. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of developing cancer vaccines, the longer time required for manufacturing a single vaccine and lengthy regulatory approvals are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cancer vaccines market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. As the number of COVID-19 cases increased, healthcare systems worldwide focused on controlling the illness and delaying the prevention, detection, and treatment of other chronic illnesses, including cancer. Researchers at the University of Oxford and AstraZeneca Plc are attempting to create a therapeutic cancer vaccine using the same technique, with encouraging findings reported in animal experiments. After the pandemic, scientists and governments worked harder and faster than ever to produce vaccines to help contain the virus. As a result, vaccine research has evolved. Because of the crisis, technologies like messenger RNA have proven their efficacy and potential to treat other diseases like cancer. The advancements come as researchers examine other cutting-edge cancer treatments that use the immune system to fight tumors.

In contrast, the pandemic interrupts the cancer vaccine supply chain and process. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Recombinant Cancer Vaccines segment is expected to hold the largest market share in the cancer vaccine market.

The recombinant cancer vaccines segment is expected to dominate in 2021. Recombinant vaccines are created using recombinant DNA technology. This involves the expression of an antigen in mammalian cells, which triggers an immunological response and purifies the antigen from these cells. Various viruses have undergone genetic modification to express tumor-associated antigens (TAA) for intramuscular or subcutaneous injection. Broad cell tropism, strong immunogenicity, and pre-existing neutralizing immunity, exclusively in those patients who received the vaccinia virus, are only a few advantageous characteristics of poxviruses as vectors for cancer vaccines (the smallpox vaccine). Canarypox, fowlpox, and vaccines have all been studied therapeutically for cancer vaccination.

Additionally, a great deal of research is being done on viral recombinant cancer vaccines, primarily for cancer vaccination, which may have favorable outcomes in the future. Therefore, it has increased the demand for recombinant cancer vaccines. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global cancer vaccines market.

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer, rising research investments, increasing clinical trials by the market players and regulatory approvals for cancer vaccines are the factors the market is driven by in the forecast period. For instance, according to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 29-31, 2020. Gilead Sciences, Inc. and Kite, a Gilead Company, announced that nine abstracts from their immuno-oncology research and development program, including three oral presentations, have been accepted. Abstracts at ASCO will showcase Kite's industry-leading cell therapy portfolio and magrolimab, an experimental anti-CD47 monoclonal antibody created by Forty-Seven, Inc., which Gilead just purchased. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the cancer vaccines market are ose-immuno, Merck & Co. Inc., IO Biotech, Medigene AG, Northwest Biotherapeutics, GlaxoSmithKline, Dendreon Pharmaceuticals LLC., Dynavax Technologies Corporation, Immunophotonics, Codagenix.

Northwest Biotherapeutics Inc.:

Overview:

Northwest Biotherapeutics Inc. is a biotechnology company involved in developing cancer vaccines. The target is a broad range of solid-tumor cancers. A customized vaccination is created by the corporation using a patented manufacturing method. The product portfolio includes product candidates such as DCVax-L for patients with brain cancer, DCVax-Direct for direct injection into all forms of solid tumor malignancies that are incurable, and DCVax for late-stage ovarian cancer. The U.S. Food and Drug Administration have given approval for DCVax-Prostate, which is used to treat late-stage prostate cancer.

Product Portfolio:

DCVAX TECHNOLOGY: DCVax is a platform technology for delivering dendritic cell based therapeutic vaccines for various cancers, including glioblastoma multiforme (GBM).

The global cancer vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
    • 4.1.2. Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.
  • 4.2. Restraints:
    • 4.2.1. The high cost of developing cancer vaccines is expected to hamper the market growth.
  • 4.3. Opportunity
  • 4.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Preventive Cancer Vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Therapeutic Cancer Vaccine

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Dendritic Cells (DC) Cancer Vaccines*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Recombinant Cancer Vaccines
  • 8.4. Antigen/Adjuvant Cancer Vaccines
  • 8.5. Whole Cell Cancer Vaccines
  • 8.6. Viral Vector & DNA Cancer Vaccines

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type Segment
  • 9.2. Prostate Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cervical Cancer
  • 9.4. Lung Cancer
  • 9.5. Bladder Cancer
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. ose-immuno*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck & Co. Inc.
  • 12.3. IO Biotech
  • 12.4. Medigene AG
  • 12.5. Northwest Biotherapeutics
  • 12.6. GlaxoSmithKline
  • 12.7. Dendreon Pharmaceuticals LLC.
  • 12.8. Dynavax Technologies Corporation
  • 12.9. Immunophotonics
  • 12.10. Codagenix(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us